Thursday, 18 June 2026

Vol. 1 · No. 16 Thursday, 18 June 2026 “A drug's route of administration is the distance between the hospital and the world.”

In this edition

This edition leads with the FDA's June 17 approval of Utebzi (tebipenem pivoxil HBr), the first oral carbapenem antibiotic in history, converting an IV-dependent drug class into an outpatient option for complicated UTI. Kardigan (Nasdaq: KARD) prices its IPO at $16/share today, raising ~$400 million to advance danicamtiv in genetic dilated cardiomyopathy — the only drug in pivotal trials for a disease with no approved therapy. The VRBPAC meets today on Moderna's MFLUSIVA (mRNA-1010), the first mRNA influenza vaccine before a U.S. advisory panel; FDA briefing documents released Monday found no major deficiencies. DAPA ACT HF-TIMI 68 reports a neutral primary endpoint (HR 0.86, 95% CI 0.68–1.08) in 2,401 acute heart failure patients, with all-cause mortality trending favorable (HR 0.66, 95% CI 0.43–1.00). A medRxiv preprint of 60,998 UK Biobank adults finds sleep irregularity predicts incident risk for 131 conditions over 9.5 years — more than double the 63 conditions linked to short sleep duration. The Hetairos AI model classifies 102 CNS tumor subtypes from standard H&E slides with 0.68 top-1 accuracy versus 0.30 for five board-certified neuropathologists, validated across 9,606 patients in Nature Cancer. The DRC Ebola BDBV outbreak holds at 808 confirmed cases while WHO issues its first comprehensive filovirus clinical management guidelines. The WISeR Act, requiring FDA to set transparency standards for AI in drug review, advances by bipartisan voice vote.

FDA & Regulatory

FDA Approves Utebzi — Tebipenem Pivoxil HBr — as the First Oral Carbapenem for Complicated UTI

The approval converts an IV-only antibiotic class into an outpatient option, potentially shifting hundreds of thousands of annual cUTI hospitalizations toward oral step-down therapy.

Regulatory Desk · 3 min read

The FDA on June 17, 2026, approved Utebzi (tebipenem pivoxil hydrobromide, 600 mg oral tablets) for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute uncomplicated pyelonephritis caused by susceptible Enterobacteriaceae. The approval, granted to GSK following the full NDA transfer from Spero Therapeutics upon GSK’s 2023 acquisition, makes tebipenem the first oral carbapenem antibiotic approved anywhere in the world.

Why an oral carbapenem matters

Continue reading →

Also leading today

FDA & Regulatory

VRBPAC Convenes Today on Moderna's MFLUSIVA, the First mRNA Influenza Vaccine Before a U.S. Advisory Panel

FDA's Vaccines and Related Biological Products Advisory Committee meets June 18 to evaluate Moderna's mRNA-1010 BLA — briefing documents released Monday found no major deficiencies.

Regulatory Desk · 2 min

Biotech Business

Kardigan Prices Nasdaq IPO at $16 per Share, Raising ~$400 Million to Advance Genetic DCM Drug Danicamtiv

The company co-founded by former MyoKardia CEO Tassos Gianakakos begins trading today as KARD, backed by Phase 2a data showing a +8.8% absolute LVEF gain in MYH7-positive patients.

Business Desk · 3 min

← The archive

Thursday, 18 June 2026 edition — The Vital Record

FDA Approves Utebzi — Tebipenem Pivoxil HBr — as the First Oral Carbapenem for Complicated UTI

Why an oral carbapenem matters

Also leading today

VRBPAC Convenes Today on Moderna's MFLUSIVA, the First mRNA Influenza Vaccine Before a U.S. Advisory Panel

Kardigan Prices Nasdaq IPO at $16 per Share, Raising ~$400 Million to Advance Genetic DCM Drug Danicamtiv